Background. We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)-positive patients receiving nucleos(t)ide analogue (NA) therapy, compared with continued NA monotherapy.
The recommended first-line treatment strategies for chronic hepatitis B virus (HBV) infection are pegylated interferon (peginterferon) monotherapy and nucleos(t)ide analogue (NA) monotherapy, such as entecavir (ETV) or tenofovir (TDF) [1] . The aim of these antiviral therapies is to prevent disease progression, such as the development of cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death, by means of sustained inhibition of HBV replication.
Peginterferon is an immunomodulatory agent that reduces the presence of covalently closed circular DNA. It stimulates the patient's immune system directly and is effective in the achievement of serological response and sustained off-treatment response, but this occurs only in 20%-30% of the treated patients [2] [3] [4] . On the other hand, NAs act directly on the HBV replication process and are therefore particularly effective in the inhibition of HBV replication. However, serological responses are rare [5] [6] [7] [8] [9] , and treatment discontinuation is only feasible in highly selected patients after HBV envelope antigen (HBeAg) seroconversion [1, [10] [11] [12] .
Additionally, it has been shown that patients with a low viral load were more responsive to peginterferon [13, 14] . Moreover, immunological studies have demonstrated a partial restoration of the host's immune system after NA treatment [15, 16] . Therefore, to increase serological response and to facilitate NA discontinuation, a potential combination strategy is to add peginterferon treatment to NA therapy. This peginterferon add-on strategy is currently being investigated in HBeAg-negative patients who have been treated with NA; preliminary results showed an increase in the frequency of HBV surface antigen (HBsAg) seroconversion [17] . In another setting, we have shown that use of NA lead-in therapy, which effectively lowered the viral load, before peginterferon add-on therapy led to more serological responses as compared to NA monotherapy in HBeAg-positive chronic hepatitis B (CHB) patients with chronic hepatitis B (CHB) [5] . Based on these observations, the question, however, remains whether the peginterferon add-on strategy in HBeAg-positive patients treated with NA can increase the frequency of serological responses. The aim of this trial was to investigate whether 48 weeks of peginterferon add-on therapy in HBeAg-positive patients treated with ETV or TDF for at least 1 year leads to an increased frequency of serological responses as compared to continued NA monotherapy.
METHODS

Trial Design
The PEGON study was an investigator-initiated, open-label, multicenter, randomized, controlled trial (clinical trials registration NCT01532843) conducted in 4 university hospitals in the Netherlands and China. Patients recruitment started in June 2012, study follow-up ended in April 2015, and the database was closed in August 2015. Patients who had been treated for at least 12 months with ETV (Baraclude, 0.5 mg once daily; BristolMyers Squibb, New York, NY) or TDF (Viread, 245 mg once daily; Gilead Sciences, Foster City, CA) were randomly assigned in a 1:1 ratio to receive peginterferon alfa-2b add-on therapy (PegIntron, 1.5 μg/kg subcutaneously once weekly; Merck, Kenilworth, NJ) for 48 weeks or to continue NA monotherapy for 48 weeks ( Figure 1A ). For both treatment arms, patients who achieved a response (defined as HBeAg seroconversion and an HBV DNA load of <200 IU/mL) at week 48 discontinued NA therapy at week 72. All patients were followed until week 96 (the end of study follow-up). Screened patients were checked for Figure 1 . A, Trial design. Patients who achieved hepatitis B virus (HBV) envelope antigen (HBeAg) seroconversion with an HBV DNA level of <200 IU/mL at week 48 were allowed to discontinue nucleos(t)ide analogue (NA) therapy at week 72. All patients were followed until week 96. B, Patient disposition during the study. Abbreviations: Anti-HBe, antibody to hepatitis B virus e antigen; HCC, hepatocellular carcinoma; mITT, modified intention to treat; peginterferon, pegylated interferon alfa-2a.
eligibility and randomly assigned to a treatment group centrally. A computer-generated randomization sequence based on random blocks of 2-6 was prepared by the trial statistician (B. H.).
This study was approved by the ethics boards of each participating site and was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Written informed consent was acquired before screening. Monitoring was performed by an independent company. All authors had access to the study data and reviewed and approved the final manuscript.
Inclusion and Exclusion Criteria
Adults with chronic hepatitis B (defined as serum HBsAg positivity for >6 months) who had been treated with either ETV or TDF for at least 12 months were enrolled in the study. Further eligibility criteria were HBeAg positivity, antibody to HBeAg (anti-HBe) negativity, and an HBV DNA load of <2000 IU/mL within 4 weeks prior to study initiation; a serum alanine aminotransferase (ALT) level of <5 times the upper limit of normal; and written informed consent. Exclusion criteria included treatment with any investigational drug within 30 days of study inclusion; history or presence of decompensated cirrhosis (defined as jaundice in the presence of cirrhosis, ascites, gastric or esophageal varices, or encephalopathy); preexistent neutropenia (neutrophil count, ≤1500 neutrophils/mm 3 ) or thrombocytopenia (platelet count, ≤90 000 platelets/mm 3 ); coinfection with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus; any other acquired or inherited liver disease; an α-fetoprotein level of >50 ng/mL; uncontrolled thyroid disease; immunosuppressive treatment within the previous 6 months; contraindications for interferon therapy; pregnancy or breast-feeding; substance abuse in the past 2 years, defined as alcohol use of ≥80 g/day or use of injected or inhaled drugs; and any medical condition requiring chronic systemic administration of corticosteroids during the study.
Primary and Secondary End Points
The efficacy analysis included all patients who fulfilled the inclusion and exclusion criteria and received at least 1 dose of the assigned medication (ie, the modified intention-to-treat [mITT] population). The primary end point was HBeAg seroconversion combined with an HBV DNA load of <200 IU/mL at week 96. Secondary end points included HBeAg seroconversion combined with an HBV DNA load of <20 IU/mL, HBeAg loss, HBeAg seroconversion, an HBV DNA level of <20 IU/mL, a decrease in the HBsAg level of >0.5 log IU/mL, and normalization of the ALT level at weeks 48, 72, and 96. For dichotomous primary and secondary end points, patients with missing data (due to loss to follow-up) for the specific end point were considered nonresponders.
Adverse Events
The adverse events analysis included all patients who were randomly assigned to one of the treatment groups. This analysis included chemistry and hematology data, which were graded according to the World Health Organization recommendations for toxicity grading, adapted for chronic liver disease.
Study Follow-up and Laboratory Tests
During peginterferon treatment, patients were followed every 4 weeks for routine examination and laboratory testing. After stopping peginterferon treatment, patients were followed every 12 weeks until the end of the study. Patients who were assigned to receive NA monotherapy were followed every 12 weeks. An additional safety visit was performed at week 76 for patients who were allowed to discontinue NA therapy at week 72.
Biochemical and hematological tests were performed locally at every visit. Serum HBV DNA loads were measured using the Cobas TaqMan polymerase chain reaction assay, with a lower limit of quantification of 20 IU/mL (Roche Diagnostics, Basel, Switzerland). Serum HBeAg, anti-HBe, and HBsAg levels (lower limits of detection, 0.05 IU/mL) were measured using the Architect (Abbott Laboratories, North Chicago, IL). Because patients were required to have a low viral load at study inclusion, it was not possible to measure the HBV genotype. Available HBV genotype data were retrospectively collected or the HBV genotype was assessed in available stored samples, using the INNOLiPA HBV genotype assay (Innogenetics, Ghent, Belgium).
Statistical Analysis
The power calculation was based on the expectation that the primary end point would occur in 32% of patients receiving peginterferon add-on therapy and 5% of patients receiving NA monotherapy. The expected peginterferon add-on response rate of 32% was based on an HBeAg seroconversion rate of 22% in patients treated with peginterferon for 48 weeks [3] and an assumed 10% higher rate due to immunological enhancement by NA-induced viral load reduction. The expected NA monotherapy response rate of 5% was based on an HBeAg seroconversion rate of 20% after 1 year of ETV or TDF therapy [18, 19] and an assumed 15% lower rate in patients who did not develop HBeAg seroconversion during the first period of NA treatment. Using the Fisher exact test set at a power of 80%, a 2-sided α of 0.05, and considering a 10% withdrawal rate, we calculated that 40 patients were required per treatment arm. Therefore, 80 patients were needed for this study.
A data analysis plan was written before the closure of the database. This predefined plan included stratified analysis for prespecified relevant covariates following the European Medicines guideline for trial analysis [20] . These prespecified covariates included race, sex, previous history of (pegylated) interferon, HBV DNA load, HBsAg level, and serum ALT levels at baseline.
Serum HBV DNA and HBsAg levels were log transformed. Serum ALT levels were standardized according to sex and the local upper limit of normal. Baseline characteristics were compared between treatment arms using the χ 2 test, the Fisher exact test, the Student t test, or the Mann-Whitney test, where appropriate. Dichotomous primary and secondary end points were analyzed using the χ 2 test or the Fisher exact test, whereas continuous secondary end points were analyzed using the Student t test. Logistic regression was used to assess the association between baseline factors and the primary end point.
Statistical analyses were performed with SPSS, version 21.0 (IBM, Armonk, NY), or SAS software, version 9.3 (SAS Institute, Cary, NC). All statistical tests were 2 sided. A P value of < .05 was considered as statistically significant.
RESULTS
Patient Population
Among the 86 patients screened, 82 met the eligibility criteria and were randomly assigned to one of the treatment groups. Figure 1B shows the patient disposition. Forty-one patients were randomly assigned to receive peginterferon add-on therapy, and 41 were randomly assigned to continue NA monotherapy. In total, 77 patients were included in the final mITT analysis; 4 patients were found to be HBeAg negative or antiHBe positive at week 0, and 1 patient withdrew his consent before receiving the intervention. The proportion of excluded patients from analysis was comparable between the 2 treatment arms (P = 1.00).
Baseline characteristics of the patients are shown in Table 1 and were comparable between treatment arms. Eight patients in the peginterferon add-on group did not complete treatment or follow-up, compared with 2 patients in the monotherapy group (P = .087). All patients received ETV, except for one patient in the peginterferon add-on group, who received TDF.
Response
The primary end point (response at week 96) was achieved by 7 of 39 patients (18%) assigned peginterferon add-on therapy, compared with 3 of 38 (8%) assigned to receive NA monotherapy (P = .31). In univariable analysis, no baseline factor was significantly associated with response at week 96 (Supplementary Table 1 ). The development of response during study follow-up is presented in Figure 2A . Secondary end points are presented in Table 2 .
According to the data analysis plan, stratified analysis for prespecified relevant covariates showed that only a previous history of (pegylated) IFN was associated with the primary end point in patients who received peginterferon add-on therapy (Supplementary Figure 1) . Among the 58 interferon-naive patients, peginterferon add-on treatment resulted in more response (Figure 2B ), as well as HBeAg seroconversion ( Figure 2C ) compared with continued NA monotherapy.
Among the 39 patients who received peginterferon add-on therapy, on-treatment HBsAg levels at week 12 (odds ratio [OR], 0.97; 95% confidence interval [CI], .39-2.40; P = .94) and week 24 (OR, 0.90; 95% CI, .41-1.97; P = .79) were not significantly associated with the primary end point in logistic regression. Further categorization of the HBsAg levels based on earlier studies was also not significantly associated with the primary end point (Supplementary Figures 2 and 3 ).
Off-Treatment Response
In total, 8 of 77 patients achieved response at week 48 (6 of 39 [15%] in the peginterferon add-on group and 2 of 38 [5%] who received monotherapy) and discontinued NA therapy at week 72 according to study protocol. Of these 8 patients, 6 patients (75%; 4 of 6 [67%] in the peginterferon add-on group vs 2 of 2 [100%] in the NA monotherapy group) maintained response until week 96 (P = 1.00). All 6 patients with a sustained response had an undetectable HBV DNA level (<20 IU/mL) and normal ALT levels until the end of study follow-up. Among the 2 patients in the peginterferon add-on group who experienced relapse, one developed HBeAg seroreversion combined with a viral load of 8.2 log IU/mL, while the other demonstrated a viral load of 6.7 log IU/mL while maintaining HBeAg negativity (Supplementary Figure 4) .
Decline in HBsAg Level
From week 0 to week 48, a greater decrease in the HBsAg level was achieved in patients who received peginterferon add-on therapy as compared to patients who continued NA monotherapy (−0.40 vs. −0.15 log IU/mL; P = .005; Figure 3 ; Supplementary Results). Furthermore, when also assessing the consolidation period (ie, week 0 to week 72), peginterferon add-on therapy led to a greater decrease in HBsAg level, compared with NA monotherapy Figure 2 . A, The development of response (defined as hepatitis B virus envelope antigen [HBeAg] seroconversion and an HBV DNA load of <200 IU/mL) throughout the study. The primary end point was response at week 96 (gray box in the table). B, The development of response (ie, HBeAg seroconversion and an HBV DNA load of <200 IU/ mL) in interferon-naive patients. C, HBeAg seroconversion in interferon-naive patients. NA, nucleos(t)ide analogue. a Results at week 96 included patients with response at week 48 who subsequently discontinued NA therapy at week 72.
(−0.35 vs −0.20 log IU/mL; P = .014; Figure 3 ). At week 72, 26% of patients in the peginterferon add-on group achieved a decline in the HBsAg level of >0.5 log IU/mL, compared with 8% of patients who received NA monotherapy (P = .038). Among the patients who discontinued therapy, the increase in HBsAg level from week 72 to week 96 was comparable between peginterferon add-on therapy and NA monotherapy (0.28 vs. 0.22 log IU/mL; P = .84).
Safety and Tolerability
Adverse events were more frequent during 48 weeks of peginterferon add-on therapy than during NA monotherapy (Table 3 ). The most common adverse events were expected to occur during peginterferon therapy, such as influenza-like syndrome, fatigue, and neutropenia. Seven patients who received peginterferon add-on therapy developed thyroid dysfunction, of whom 6 had hyperthyroidism (3 had subsequent hypothyroidism and 1 had subclinical hypothyroidism). Peginterferon therapy was discontinued or interrupted in 5 of the 7 patients. One patient was treated with antithyroid medication, and 1 required thyroid hormone replacement. The thyroid dysfunction was transient in 5 of the 7 patients (mean duration of dysfunction, 50 weeks) and resolved during study follow-up. In total, 3 severe adverse events (SAEs) occurred: 1 (2%) occurred in the peginterferon add-on group, and 2 (5%) occurred in the NA monotherapy group (P = 1.00). The patient who received peginterferon add-on had a right navicular bone fracture at study week 7. The 2 SAEs (electrocardiography-proven atrial fibrillation at week 26 and atrial flutter at week 36) in the NA monotherapy group occurred in the same patient. All SAEs were reversible and deemed to be unrelated to the study medication.
DISCUSSION
In this randomized, controlled trial of HBeAg-positive patients receiving NA therapy, peginterferon add-on therapy led to a numerically higher HBeAg seroconversion rate, which was however not statistically different from the rate for the group of patients who continued NA monotherapy. However, the peginterferon add-on strategy appeared to result in a greater HBeAg response in the subgroup of interferon-naive patients.
One of the rationales of peginterferon add-on therapy in NA-treated patients with a very low viral load was the early clinical observation that patients with a low viral load were more responsive to peginterferon [3, 13, 14] . Also, treatment with NA and a subsequent viral load reduction have been shown to restore the responsiveness of T lymphocytes and natural killer cells in patients with CHB [15, 16, 21] . Therefore, the addition of peginterferon, an immune-modulating agent, after NA pretreatment may increase serological responses, which occur infrequently during NA therapy [7, 9, 22] .
Recently, there has been a resurgence of studies on the combination of peginterferon and NA [23] . Earlier studies have shown that concurrent initiation of peginterferon with lamivudine therapy was not better than peginterferon monotherapy [3, 24] . However, recent data from a large study showed that the concurrent initiation of peginterferon and TDF therapy led to somewhat more HBsAg seroclearance, compared with monotherapy with either peginterferon or TDF [25] . Interestingly, in a randomized trial (the OSST study) of ETV-treated HBeAgpositive patients, Ning et al showed that more HBeAg seroconversion and HBsAg loss were observed in patients who switched to 48-week peginterferon treatment, compared with those who continued ETV treatment [26] . Important to note is that patients had low levels of serum HBeAg (<100 Paul Ehrlich Institute Units/mL) at the time of randomization in that study. We recently demonstrated that addition of peginterferon after a 6-month lead-in ETV treatment period was effective in treatment-naive HBeAg-positive patients (the ARES study) [5] . In that study, peginterferon add-on treatment increased serological and off-treatment responses, compared with ETV monotherapy. As for HBeAg-negative patients, recent data showed that HBsAg seroconversion occurred more often in patients who received peginterferon add-on therapy than in patients who continued NA monotherapy [17] .
The limited effect of peginterferon add-on therapy as observed in this study can be explained by several factors. First, our patient population might have been difficult to treat as it consisted of patients who had been treated with ETV or TDF for a median of 2.4 years without HBeAg seroconversion. Second, almost all patients were of Asian origin, except for 4 Caucasian patients, who were all infected with genotype D. Among the major HBV genotypes, genotype D is associated with the lowest chance of response to peginterferon [14] . Furthermore, most of our Asian patients appeared to be infected with genotype C, which is also associated with a lower chance of response, compared with genotype B [27] . Third, 25% of the patients had a history of (pegylated) IFN nonresponse. Previous nonresponse might be caused by unfavorable viral genotypes and host genetic variations, such as polymorphisms of HLA-DP or IL28B [28] [29] [30] . Finally, we may have missed a significant difference between the 2 treatment arms because of a type II error. Nonetheless, in our study population, in which most patients had NA-induced serum HBV DNA negativity for several years, peginterferon add-on therapy did not appear to be the pivotal solution to increase serological responses.
We have previously shown that on-treatment HBsAg levels were useful for the prediction of response in patients with CHB who were undergoing peginterferon treatment [31, 32] . This individualized on-treatment approach could not be reproduced in the PEGON study. First, previous prediction rules may not be directly extrapolated to the PEGON study, owing to the difference in study population and design. Second, the number of responses was low, which limited the power to explore the HBsAg-guided approach. Yet, in this difficult-to-treat group of patients who may need to continue NA treatment for an indefinite period, issues such as compliance, side effects, and costs should not be neglected [12, 33] . Peginterferon is currently the only finite treatment option. Obviously, the side effects of peginterferon treatment should also be considered. Larger studies are needed to identify baseline and on-treatment predictors of the response to peginterferon add-on therapy. In a subgroup analysis, we observed that interferon-naive patients benefitted the most from peginterferon add-on therapy, whereas none of the interferon-experienced patients responded to peginterferon add-on therapy. Important to note is that our study was not designed to investigate the efficacy of peginterferon add-on treatment in interferon-naive patients. More studies are warranted in this patient group before further recommendations are given. A limited number of patients (8) were able to discontinue NA therapy according to the study protocol. The majority of these patients maintained an off-treatment response for up to 6 months of follow-up. Yet, from these data alone, it was not possible to elucidate whether peginterferon add-on therapy prevents relapse after discontinuation of NA therapy, owing to the limited number of patients who discontinued NA therapy and the short off-treatment follow-up period. Therefore, longterm follow-up studies are being conducted. The fact that posttreatment HBsAg levels tended to increase in this study may be attributed to the short consolidation duration. Studies have suggested that prolongation of consolidation therapy to at least 3 years might be needed to reduce relapses [12, 34] .
The observed adverse events were expected for peginterferon treatment. Seventeen percent of patients in the add-on treatment group developed thyroid dysfunction, which is a wellknown side effect of interferon alfa treatment [35] . However, this side effect should be taken into account when considering peginterferon add-on treatment. A Greek study reported an incidence of 9.4% for patients with CHB treated with interferon alfa monotherapy [36] , while a recent Chinese study observed thyroid disorders in 23% of patients who received peginterferon and adefovir combination therapy [37] . Fortunately, the thyroid disorders were transient in the majority of our patients. Overall, add-on treatment with peginterferon was well tolerated.
A limitation is that the HBV genotype was not known for less than half of the patients owing to the study design. The viral load in eligible patients was well suppressed with ETV or TDF therapy, and it was therefore not possible to test the genotype. With the available viral genotype information, it seemed that a majority of our patients were infected with genotype C, with the next highest proportion infected with genotype B. Our results are therefore of particular interest to Asian patients, who currently represent the largest segment of patients that remain HBeAg positive during NA therapy.
In conclusion, in a predominantly Asian population of HBeAg-positive patients treated with ETV or TDF, peginterferon add-on therapy did not lead to significantly more HBeAg seroconversion, compared with continuation of NA monotherapy. However, in the subgroup of interferon-naive patients, peginterferon add-on therapy appeared to result in a greater HBeAg response. These data need to be confirmed in future studies.
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